Financial News Discussion of SVNT - Savient Pharmaceuticals, Incorporated on The Opening Bell on Fox Business

Financial News for Savient Pharmaceuticals, Incorporated (SVNT)

SVNT 3/19/2010 4:00PM 52 Week Price Range Market Capitalization Dividend Yield Recent Dividend
$14.57 $4.38 — $16.62 $992.9 Million n/a n/a

Want to Sharpen Your Investing?

Learn how Ockham can help investors make informed decisions and slice through the noise. Learn more about Ockham's services.

Sign Up Now for Ockham's Stock Analysis and News Services

Explore Why Ockham?

Quality Analysis
Ockham has fundamental valuations on over 5000 companies which we distribute, to our clients via highly-focused equity reports, weekly newsletters, and analysts' daily market commentary blogs. (Learn More)
Crowd Sentiment
Through our partnership with The Motley Fool, Ockham provides the most robust data on investors' sentiment of individual stocks. This indicator, along with our valuations and our news tracking, helps our clients make informed investment decisions. (Learn More)
Financial News Slicing
With the influx of noise in our lives, it can be exceedingly difficult to separate the essential news from everything else. Ockham's RazorWire tool "slices" through business television and impactful blogs to provide you with the clearest information possible. (Learn More)
Savient Pharmaceuticals, Inc. was discussed on The Opening Bell on Fox Business which was originally produced by Fox Business on 8/3/2009
The Opening Bell on Fox Business discussed Savient Pharmaceuticals, Incorporated on 8/3/09. Alexis Glick, who highlights news and stocks each day at 9:00 AM, mentioned Savient Pharmaceuticals, Incorporated on the program. The mention with surrounding context is displayed below.

Savient Pharmaceuticals, Incorporated is in the news. Find out how this impacts SVNT trading on Ockham Research.

Ford shares up 10% already in the early going here op optimism over july sales, senior execs saying that the auto maker on track to report its first monthly sales gain in two years. And number one, SAVIENT PHARMACEUTICALS saying that the food and drug administration declined to approve on its drug for chronic gout. The approval was widely expected by shareholders here.

“inistration declined to approve on its drug for chronic gout. The approval was widely expected by shareholders here. ” The Opening Bell on Fox Business Aug 3, 2009 9:38 AM
A couple other items to be aware of: